Huntsville, Ala. — Serina Therapeutics announced today that the company has entered into a research agreement with the Scripps Research Institute for development of polymer-antibody drug conjugates.
“Antibody drug conjugates represent one of the most exciting areas of drug development in oncology,” said Randall Moreadith, president and chief executive officer of Serina Therapeutics. “The ability to target antibodies that are “pay-loaded” with a potent cytotoxic agent has started to produce the first generation of approved antibody drug conjugates. Our polymer technology platform is uniquely suited to advance this field. We are very excited about working with some of the premier antibody scientists in the world at the Scripps Research Institute to develop next-generation ADCs.”
To read the full release, visit Serina’s website here.
About HudsonAlpha
The HudsonAlpha Institute for Biotechnology in Huntsville, Alabama, is the cornerstone of the Cummings Research Park Biotechnology Campus. The campus hosts a synergistic cluster of life sciences talent – science, education and business professionals – that promises collaborative innovation to turn knowledge and ideas into commercial products and services for improving human health and strengthening Alabama’s progressively diverse economy. The non-profit institute is housed in a state-of-the-art, 270,000 square-ft. facility strategically located in the nation’s second largest research park. HudsonAlpha has a three-fold mission of genomic research, economic development and educational outreach.
